Champions Biotechnlg (CSBR) 0.6900 $CSBR Champi
Post# of 273257
Posted On: 04/12/2015 8:17:32 AM
Champions Biotechnlg (CSBR) 0.6900 $CSBR
Champions Oncology's (CSBR) CEO Joel Ackerman on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:15AM CDT
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2015
PR Newswire - Tue Mar 17, 7:30AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2015.
InsiderInsights.com Daily Round Up 3/13/15: KMI, DO, CSBR, WIW
InsiderInsights - at Seeking Alpha - Sun Mar 15, 12:38AM CDT
KMI: 42.93 (+0.59), PCYC: 258.35 (+0.57), PATK: 60.90 (+1.20), WAL: 29.30 (+0.04), WETF: 22.37 (+0.58), SAM: 270.76 (-2.07), DIS: 106.95 (+0.18), MLNK: 3.83 (+0.01), SJI: 53.82 (+0.58), ASYS: 10.77 (+0.04), OWW: 11.67 (-0.02), GGP: 28.81 (-0.14), DO: 29.61 (-0.85), WIW: 11.29 (-0.08), WLB: 28.35 (+0.27), ALCO: 50.42 (+0.42), AVGO: 126.82 (-0.40), EIGI: 22.10 (+1.12)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 17
PR Newswire - Fri Mar 13, 3:00PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2015, on Tuesday, March 17, 2015, before market open.
Champions Oncology Announces $14 Million Capital Raise
PR Newswire - Thu Mar 12, 7:30AM CDT
Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the completion of a $14 million capital raise at a price of $0.40 per unit (each unit comprised of one share of common stock and a warrant to purchase 0.55 shares of common stock) through a private placement. The financing was led by new investor New Enterprise Associates, one of the world's largest venture capital firms with a significant focus in healthcare. The financing also included participation from existing institutional investors, including Battery Ventures, Perceptive Advisors and Sabby Capital. One of the Company's directors, Daniel Mendelson, also participated in the financing. The financing also reflects the conversion of the convertible promissory notes, dated December 1, 2014, of $1 million each, by Joel Ackerman, CEO, and Ronnie Morris, President. The financing was approved by a special committee of the Board of Directors.
Champions Oncology Extends Convertible Debt Financing
PR Newswire - Mon Mar 02, 9:25AM CST
Champions Oncology, Inc. (OTC-PINK: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 30 day extension on the $2 million convertible promissory notes with two of its executive officers executed on December 1, 2014.
Champions Oncology posts higher loss from operations of USD3.7m for Q2 2014
M2 - Mon Dec 15, 6:02AM CST
Oncology drug company Champions Oncology (Other OTC:CSBR) stated on Friday its loss from operations of USD3.7m for the second quarter ended 31 October 2014.
Champions Oncology Reports Results for the Second Quarter Ended October 31, 2014
PR Newswire - Fri Dec 12, 7:30AM CST
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014.
Champions Oncology to Announce Second Quarter Financial Results on Friday, December 12
PR Newswire - Tue Dec 09, 3:01PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2014, on Friday, December 12, 2014, before market open.
Presentations at 26th EORTC-NCI-AACR Symposium Highlight Champions Oncology TumorGrafts' Ability to Evaluate Immune-Modulating Therapies and Guide Clinical Development Strategies
PR Newswire - Wed Nov 19, 7:00AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held Nov. 18-21 in Barcelona, Spain, discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 66.37 (-0.77)
Presentations at Two Upcoming Oncology Conferences to Highlight Benefits of Champions Oncology TumorGrafts
PR Newswire - Thu Oct 16, 3:35PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Champions' TumorGrafts® are the subject of presentations at the Connective Tissue Oncology Society Annual Meeting and the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Data from Study of Champions Oncology TumorGrafts to be Presented at European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Wed Sep 24, 7:55AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that data from a study of Champions' TumorGrafts® will be presented on Monday, Sept. 29, at the European Society for Medical Oncology (ESMO) 2014 Congress.
Champions Oncology posts higher loss from operations for Q1 2014
M2 - Fri Sep 12, 7:17AM CDT
Oncology drug company Champions Oncology (Other OTC:CSBR) Thursday reported its loss from operations of USD3.7m for the first quarter of 2015.
Champions Oncology Reports Results for the First Quarter Ended July 31, 2014
PR Newswire - Thu Sep 11, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2014.
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 11
PR Newswire - Tue Sep 09, 9:43AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2014, on Thursday, September 11, 2014, after market close.
Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014
PR Newswire - Thu Jul 24, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24
PR Newswire - Mon Jul 21, 4:28PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014, on Thursday, July 24, 2014, after market close.
Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer
PR Newswire - Tue Jun 17, 7:00AM CDT
Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.
Champions Oncology's (CSBR) CEO Joel Ackerman on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:15AM CDT
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2015
PR Newswire - Tue Mar 17, 7:30AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2015.
InsiderInsights.com Daily Round Up 3/13/15: KMI, DO, CSBR, WIW
InsiderInsights - at Seeking Alpha - Sun Mar 15, 12:38AM CDT
KMI: 42.93 (+0.59), PCYC: 258.35 (+0.57), PATK: 60.90 (+1.20), WAL: 29.30 (+0.04), WETF: 22.37 (+0.58), SAM: 270.76 (-2.07), DIS: 106.95 (+0.18), MLNK: 3.83 (+0.01), SJI: 53.82 (+0.58), ASYS: 10.77 (+0.04), OWW: 11.67 (-0.02), GGP: 28.81 (-0.14), DO: 29.61 (-0.85), WIW: 11.29 (-0.08), WLB: 28.35 (+0.27), ALCO: 50.42 (+0.42), AVGO: 126.82 (-0.40), EIGI: 22.10 (+1.12)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 17
PR Newswire - Fri Mar 13, 3:00PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2015, on Tuesday, March 17, 2015, before market open.
Champions Oncology Announces $14 Million Capital Raise
PR Newswire - Thu Mar 12, 7:30AM CDT
Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the completion of a $14 million capital raise at a price of $0.40 per unit (each unit comprised of one share of common stock and a warrant to purchase 0.55 shares of common stock) through a private placement. The financing was led by new investor New Enterprise Associates, one of the world's largest venture capital firms with a significant focus in healthcare. The financing also included participation from existing institutional investors, including Battery Ventures, Perceptive Advisors and Sabby Capital. One of the Company's directors, Daniel Mendelson, also participated in the financing. The financing also reflects the conversion of the convertible promissory notes, dated December 1, 2014, of $1 million each, by Joel Ackerman, CEO, and Ronnie Morris, President. The financing was approved by a special committee of the Board of Directors.
Champions Oncology Extends Convertible Debt Financing
PR Newswire - Mon Mar 02, 9:25AM CST
Champions Oncology, Inc. (OTC-PINK: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 30 day extension on the $2 million convertible promissory notes with two of its executive officers executed on December 1, 2014.
Champions Oncology posts higher loss from operations of USD3.7m for Q2 2014
M2 - Mon Dec 15, 6:02AM CST
Oncology drug company Champions Oncology (Other OTC:CSBR) stated on Friday its loss from operations of USD3.7m for the second quarter ended 31 October 2014.
Champions Oncology Reports Results for the Second Quarter Ended October 31, 2014
PR Newswire - Fri Dec 12, 7:30AM CST
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2014.
Champions Oncology to Announce Second Quarter Financial Results on Friday, December 12
PR Newswire - Tue Dec 09, 3:01PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2014, on Friday, December 12, 2014, before market open.
Presentations at 26th EORTC-NCI-AACR Symposium Highlight Champions Oncology TumorGrafts' Ability to Evaluate Immune-Modulating Therapies and Guide Clinical Development Strategies
PR Newswire - Wed Nov 19, 7:00AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held Nov. 18-21 in Barcelona, Spain, discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions' TumorGrafts® in guiding clinical development strategy.
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 66.37 (-0.77)
Presentations at Two Upcoming Oncology Conferences to Highlight Benefits of Champions Oncology TumorGrafts
PR Newswire - Thu Oct 16, 3:35PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Champions' TumorGrafts® are the subject of presentations at the Connective Tissue Oncology Society Annual Meeting and the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Data from Study of Champions Oncology TumorGrafts to be Presented at European Society for Medical Oncology (ESMO) 2014 Congress
PR Newswire - Wed Sep 24, 7:55AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that data from a study of Champions' TumorGrafts® will be presented on Monday, Sept. 29, at the European Society for Medical Oncology (ESMO) 2014 Congress.
Champions Oncology posts higher loss from operations for Q1 2014
M2 - Fri Sep 12, 7:17AM CDT
Oncology drug company Champions Oncology (Other OTC:CSBR) Thursday reported its loss from operations of USD3.7m for the first quarter of 2015.
Champions Oncology Reports Results for the First Quarter Ended July 31, 2014
PR Newswire - Thu Sep 11, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2014.
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 11
PR Newswire - Tue Sep 09, 9:43AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2014, on Thursday, September 11, 2014, after market close.
Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2014
PR Newswire - Thu Jul 24, 3:01PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2014.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 24
PR Newswire - Mon Jul 21, 4:28PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2014, on Thursday, July 24, 2014, after market close.
Icahn School of Medicine at Mount Sinai and Champions Oncology Initiate Study Evaluating TumorGrafts' Ability to Predict Treatment Benefit in Patients with Triple-Negative Breast Cancer
PR Newswire - Tue Jun 17, 7:00AM CDT
Icahn School of Medicine at Mount Sinai and Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.
(0)
(0)Scroll down for more posts ▼